| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
HORSHAM, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the publication of a new peer-reviewed study in Lasers in Medical Science that reinforces the Company's commitment to personalized medicine. The study demonstrates that treatment using the Company's XTRAC 308nm Excimer Laser in combination with 0.1% tacrolimus ointment significantly improves outcomes in patients with plaque-type psoriasis compared to topical monotherapy.
The study, titled "Clinical efficacy of 308 nm excimer laser irradiation combined with 0.1% tacrolimus ointment in the treatment of plaque-type psoriasis," was authored by Xiaobin Gao, Shuhua Du, Jun Zeng, Yan Li, and Dan Shen and published in Lasers in Medical Science (2025, Vol. 40:342). DOI: https://doi.org/10.1007/s10103-025-04599-1.
Posted In: SSKN
